Prostate carcinoma is a highly prevalent biologically and clinically diverse disease,
generally associated with a consistent elevation of prostate-specific antigen levels …

Non-metastatic castration-resistant prostate cancer (nmCRPC) is a heterogeneous disease
with variable potential in developing into overt metastases. It is an area of increased unmet …

Objective: To compare the efficacy and safety of current systemic combination therapies for
patients with mHSPC and help select candidates for optimal treatment. Methods: Databases …

The FDA has approved three androgen receptor inhibitors—enzalutamide, apalutamide,
and darolutamide—for the treatment of patients with nonmetastatic castration-resistant …

ABSTRACT Introduction: Prostate cancer (PCa) is currently the second most common
cancer affecting men worldwide. Metastatic castration-resistant prostate cancer (mCRPC) is …

Non-metastatic castration-resistant prostate cancer (nmCRPC) is defined by a progressively
rising prostate-specific antigen level, despite a castrate level of testosterone, in the absence …

Background Abiraterone acetate plus prednisolone is approved to treat patients with
castration-resistant prostate cancer. This study evaluated the safety and efficacy of …

Prostate cancer (PCa) is typically treated by inhibiting androgen receptor (AR) signaling
through surgical or medical castration. Although this therapy can result in absolute remission …

Prostate cancer (PCa) is among the most diagnosed cancers in men worldwide as well as
one of the most common causes of cancer-related deaths. Despite the advances in …

Although alternative anti‑androgen therapy (switching to secondary anti‑androgens) is no
longer recommended in the clinical guidelines of prostate cancer in light of the new …